QUINIDINE GLUCONATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hibrow Hlthcare	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	212589	ANDA	Eywa Pharma Inc	71930-016-12	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (71930-016-12)	2022-03-20
Sun Pharm Industries	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	089338	ANDA	Golden State Medical Supply	51407-288-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (51407-288-01)	1987-02-11
Sun Pharm Industries	QUINIDINE GLUCONATE	quinidine gluconate	TABLET, EXTENDED RELEASE;ORAL	089338	ANDA	Sun Pharmaceutical Industries, Inc.	53489-141-01	100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53489-141-01)	1987-02-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Quinidine Gluconate is a well-established antiarrhythmic agent used primarily for the treatment of atrial fibrillation with rapid ventricular response and certain types of ventricular arrhythmias. As a complex chemical compound, it’s critical for healthcare providers and pharmaceutical companies to maintain a reliable supply chain. This article provides an in-depth analysis of the leading suppliers globally, exploring manufacturing sources, regional availability, and strategic considerations for procurement.

Overview of Quinidine Gluconate

Quinidine Gluconate, a salt form of quinidine, possesses both pharmacological efficacy and proprietary considerations affecting its supply chain. It is often supplied in sterile injectable formulations, critical for hospital-wide antiarrhythmic management [1].

The scarcity of some raw materials, regulatory considerations, and geopolitical factors influence its global supply chain. Consequently, identifying dependable suppliers necessitates understanding the manufacturing landscape and regional regulatory approvals.

Global Manufacturing Landscape

Major Pharmaceutical Manufacturers

The production of Quinidine Gluconate is dominated by pharmaceutical companies specializing in antiarrhythmic agents, sterile injectables, and complex chemical synthesis. The following are the principal players:

Akorn, Inc.
Akorn is a US-based pharmaceuticals manufacturer with extensive experience in sterile injectable products. Although some of its cardiovascular product portfolio has been acquired from other firms, Akorn remains a notable supplier in North America.
Baxter International Inc.
Baxter produces a broad range of sterile injectable drugs, including antiarrhythmics. Its manufacturing facilities in the United States, Europe, and Asia ensure regional supply resilience.
Pfizer Inc.
Historically, Pfizer has supplied various antiarrhythmic drugs, including quinidine formulations. Their global manufacturing network and rigorous regulatory compliance position Pfizer as a leading supplier in multiple markets.
Teva Pharmaceutical Industries Ltd.
As a major generic pharmaceuticals producer, Teva supplies several injectables, which could encompass quinidine gluconate, especially for markets with generic drug demand.
European Pharmaceutical Companies
In Europe, smaller regional manufacturers such as Novartis, Sanofi, and regional generics producers may supply quinidine gluconate, often under different branding or as part of broader antiarrhythmic portfolios.

Manufacturing Challenges and Raw Material Procurement

The key raw material for quinidine gluconate synthesis is quinidine base, derived chiefly from cinchona bark extracts, alongside gluconic acid for salt formation. The supply chain is sensitive to:

Cinchona bark availability
Factors impacting the raw material include climate changes affecting plantations in regions like South America and Southeast Asia.
Chemical synthesis complexities
The synthesis process involves multiple steps with strict quality controls, making manufacturing sensitive to regulatory standards.
Regulatory compliance and quality assurance
Manufacturing facilities must comply with Good Manufacturing Practices (GMP), often limiting production to licensed facilities approved by authorities such as the FDA, EMA, or respective regional agencies.

Regional Suppliers and Market Dynamics

North America

In North America, the supply of quinidine gluconate predominantly comes from large pharmaceutical companies such as Akorn and Baxter. The regional demand is stable, with hospital pharmacies and specialty clinics acting as primary purchasers.

US Market Dynamics: The FDA’s stringent approval process influences manufacturing licenses, concentration, and supply chain robustness. The FDA-approved manufacturing facilities for sterile injectables are fewer, resulting in reliance on a limited supplier base.

Europe

European suppliers include both multinational corporations (e.g., Sanofi, Novartis) and regional producers. Regulatory approval via the EMA facilitates market access across European Union member states, often requiring specific manufacturing standards.

Asia-Pacific

The Asia-Pacific region hosts several generic producers who manufacture quinidine gluconate, often at lower costs. These include:

Sandoz (Novartis affiliate)
Shandong Xinhua Pharmaceutical (China)
Yunnan Baiyao Group (China)

Manufacturers in this region benefit from lower production costs but must navigate regulatory hurdles for export and approval in Western markets.

Emerging Markets

Emerging markets in Latin America, Africa, and Southeast Asia are heavily reliant on regional generic manufacturers or imports from established producers. Supply chain risks include political instability, regulatory changes, and raw material shortages.

Key Factors Influencing Supplier Selection

Regulatory approval status
Suppliers must hold current approvals from relevant authorities, including FDA, EMA, or regional agencies.
Manufacturing capacity and lead time
Availability of sufficient production capacity influences supply reliability, especially amid increased demand during disease outbreaks.
Quality certifications
GMP compliance and batch consistency are non-negotiable in critical injectable drugs like quinidine gluconate.
Pricing and contractual flexibility
Cost considerations and supply agreements impact procurement strategies, particularly for healthcare institutions with budget constraints.
Regional distribution capabilities
Preference tends toward suppliers with robust distribution channels to ensure timely delivery across regions.

Supply Chain Risks and Mitigation

The pharmaceutical supply of quinidine gluconate faces several risks:

Raw Material Scarcity: Variations in cinchona bark harvests impact quinidine base availability. Substitute synthetic routes or alternative raw materials could mitigate this.
Regulatory Changes: Stringent approval processes may restrict raw material export or manufacturing license renewal.
Geopolitical Factors: Trade restrictions, tariffs, or regional conflicts can disrupt supply.
Manufacturing Disruptions: Natural disasters, labor strikes, or health crises like the COVID-19 pandemic can cause production halts.

Mitigation strategies include diversifying supplier bases, maintaining strategic stockpiles, and engaging with multiple regional manufacturers.

Conclusion

The global supply landscape for Quinidine Gluconate hinges on a limited pool of manufacturers equipped with validated GMP facilities. While North American and European companies such as Baxter and Pfizer dominate the high-value injectable market, regional generic producers in Asia-Pacific provide cost-effective alternatives.

Healthcare providers and pharmaceutical companies must prioritize supplier validation, ensure regulatory compliance, and develop diversified sourcing strategies to mitigate supply risks and guarantee reliable access to this critical antiarrhythmic drug.

Key Takeaways

Dominant Global Suppliers: Major players include Baxter, Pfizer, Akorn, and regional generic manufacturers. Their regulatory compliance and manufacturing capacity are crucial for supply stability.
Regional Variations: North America and Europe rely on established multinational manufacturers, whereas Asia-Pacific hosts numerous generic producers offering cost-effective options.
Supply Chain Risks: Raw material availability, regulatory changes, geopolitical factors, and manufacturing disruptions significantly impact supply continuity.
Procurement Strategies: Diversification, strategic stockpiling, and establishing strong supplier relationships are fundamental for minimizing risks.
Regulatory and Quality Standards: Ensuring suppliers meet GMP and hold necessary approvals remains paramount for drug safety and efficacy.

FAQs

1. What are the main raw materials used in manufacturing Quinidine Gluconate?
The primary raw material is quinidine base, derived from cinchona bark, combined with gluconic acid to produce the salt form used in injections. Synthetic routes are also employed, utilizing chemical synthesis pathways.

2. Which regions have the most reliable suppliers for Quinidine Gluconate?
North America and Europe feature the most reliable suppliers due to stringent regulatory oversight and established manufacturing infrastructure. Asian generic manufacturers also supply the drug at potentially lower costs but may face regulatory and quality assurance challenges.

3. Are there any recent shortages of Quinidine Gluconate globally?
While shortages are relatively rare due to its established manufacturing processes, disruptions have occurred during the COVID-19 pandemic, primarily due to raw material supply issues or manufacturing closures.

4. How do regulatory considerations influence supplier choice?
Regulatory approval by agencies like the FDA or EMA ensures compliance with safety, efficacy, and quality standards, influencing procurement decisions. Suppliers lacking current approvals may be excluded from certain markets.

5. Can synthetic methods replace natural raw materials in quinidine production?
Yes, synthetic pathways are increasingly used to reduce reliance on cinchona bark, enhance supply chain stability, and meet regulatory standards, especially amid raw material scarcity.

Sources:

[1] Martindale: The Complete Drug Reference, 38th Edition, Pharmaceutical Press, 2020.

Suppliers and packagers for generic pharmaceutical drug: QUINIDINE GLUCONATE